ERBB2 and breast cancer: Therefore, we hypothesize that (i) DVL2 depletion will reduce the expression of classic oncogenic Wnt markers involved in cancer cell proliferation and invasion in HER2-overexpressed in vitro models of breast cancer, and (ii) clinically, high DVL2 protein expression will modulate markers of TIL infiltrations and cytotoxicity such as TIL score, CD8α, and NLR/PLR, eventually resulting in poor survival outcomes in HER2+ breast cancer.